OncoMatch/Clinical Trials/NCT07823855
SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC
Official title: A Single-arm Phase I/II Clinical Study of Simultaneous Integrated Boost Accelerated Hyperfractionated Radiotherapy for High-proliferation Non-small Cell Lung Cancer
Is NCT07823855 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for non-small cell lung cancer.
This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost accelerated hyperfractionated radiotherapy in patients with high-proliferation non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Lab requirements
Cardiac function
Severe cardiac disease (NYHA functional class ≥ III, uncontrolled arrhythmia, or myocardial infarction within the past 6 months)
Severe cardiac disease (New York Heart Association [NYHA] functional class ≥ III, uncontrolled arrhythmia, or myocardial infarction within the past 6 months)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07823855 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages